Europska Unija - hrvatski - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cjepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - ne više od tri od sljedećih pročišćena, инактивированная noga-i-usta bolest sojeva virusa: o1 manisa ≥ 6 pd50*; o1 БФС ≥ 6 pd50*; oa tajvan 3/97 ≥ 6 pd50*; a22 irak ≥ 6 pd50*; a24 Крузейро ≥ 6 pd50*; turska 14/98 ≥ 6 pd50*; azija-1 Шамир ≥ 6 pd50*; sat2 saudijskoj arabiji ≥ 6 pd50*; * pd50 – 50% sigurnosni prijem u uzgoj, kao što je opisano u filozofiji eura. 0063 monografije. - immunologicals - pigs; cattle; sheep - aktivna imunizacija goveda, ovaca i svinja od 2 tjedna protiv slinavke i šapa radi smanjenja kliničkih znakova.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - ovca - aktivna imunizacija ovaca od 1. 5 mjeseci starosti kako bi se spriječila viremija uzrokovana virusom bolesti plavog jezika, serotipovima 1 i 8. početak imuniteta: 21 dan nakon završetka primarne sheme cijepljenja. trajanje imuniteta: 12 mjeseci.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa  - inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus - immunologicals - mačke - za aktivna imunizacija zdravih mačaka devet tjedana i stariji protiv панлейкопении i virus mačje leukemije i protiv respiratornih bolesti uzrokovane virusom ринотрахеита mačke, mačka калицивирус i klamidija feliz.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer, recombinant type-d pasteurella-multocida toxin - immunologicals - svinje (nazimice i krmače) - za pasivne zaštite поросятам kroz kolostrum nakon aktivne imunizacije krmača i popravak svinje za smanjenje kliničkih znakova i poraza progresivni i непрогрессивный атрофическом рините, ali i da se smanji gubitak težine povezan s Бордетеллы-bronchiseptica i pasteurella-multocida infekcije u razdoblju tova. zadatak istraživanja su pokazala da je pasivni imunitet kod prasadi traje do šest tjedana, dok u kliničkim terenska ispitivanja, blagotvoran utjecaj cijepljenja (smanjenje nosa poraza i rezultat gubitka težine) uočeni do klanja.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunološke za suidae - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split virusa influence, inaktiviran, koji sadrži antigen: a / vietnam / 1194/2004 (h5n1) kao soj koji se koristio (nibrg-14) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.